Mechanistic Study of ISIS ISIS-APOCIIIRX in Type 2 Diabetes

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Type 2 Diabetes

In brief

The purpose of this study is to evaluate the effects of ISIS ISIS-APOCIIIRX on Triglyceride Levels and Insulin Sensitivity in Subjects with Type 2 Diabetes on stable treatment with metformin.

Key facts

Study ID

NCT01647308

Run by

Ionis Pharmaceuticals, Inc.

People needed

15

Starts

2012-07-01

Expected to finish

2014-03-01

Last updated by the study team

2022-01-18

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• BMI >/= 25 to </= 40 kg/m2
• Type 2 Diabetes Mellitus and on a stable dose of metformin
• Hypertriglyceridemia

You may not qualify if…

• Significant abnormalities in medical history, clinical examination or clinical testing
• Use of oral anti-diabetic medication other than metformin within 3 months prior to dosing
• History of outpatient insulin use for more than 2 weeks in the last year

Where it is running

• Profil Institute for Clinical Research — Chula Vista, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.